Aemetis Stock Price, News & Analysis

Aemetis, Inc. (NASDAQ:AMTX) reported its financial results for Q3 2020, showing revenues of $40.9 million, down from $57.4 million in Q3 2019. The net loss was $12.2 million, compared to $7.2 million the previous year. Ethanol and high-grade alcohol sales increased by 11%, while biodiesel sales surged 216% compared to Q2 2020. The company achieved milestones in its dairy biogas project and launched Aemetis Health Products to meet sanitizer demand. Total revenues for the first nine months of 2020 were $128.2 million, an 14.6% decline from 2019.

Aemetis, Inc. (NASDAQ: AMTX) will host a conference call to discuss its third quarter 2020 earnings report on November 12, 2020, at 11 am PST. Interested parties can participate via toll-free and international dial-in numbers or through a webcast available on the company's website. The earnings report will be accessible after November 19, 2020, for further review. Aemetis is engaged in renewable fuels and biochemical technologies, operating facilities in California and India, with a focus on converting traditional petroleum products into advanced biorefineries.

Aemetis, Inc. (NASDAQ: AMTX) has initiated production of dairy biogas from two dairies as part of a larger 17-dairy biogas project. This below-zero carbon intensity gas is being used for ethanol production at the Aemetis facility in California. The company plans to scale up its operations, adding 15 more digesters and related infrastructure. The funding plan for this project includes over $65 million in preferred equity and grants. This initiative provides a new revenue stream for local dairies and meets California's methane emission reduction goals.

Aemetis, Inc. (NASDAQ: AMTX) has initiated production of hand sanitizer under its Aemetis Health Products label, targeting government and consumer markets. The company's California facility is noted as the largest hand sanitizer alcohol producer in the Western U.S., eliminating long transport times for sanitizer products. Aemetis hand sanitizer contains 70% to 80% alcohol, meeting FDA standards. The company aims to provide safe, domestic products while supporting U.S. jobs and addressing the demand for sanitizer.

Aemetis, Inc. (NASDAQ: AMTX) has successfully closed its Phase I EB-5 Program, raising $35.5 million from 71 foreign investors. The funds will generate direct and indirect jobs at its ethanol plant in California. All investors have been vetted by the U.S. Department of Homeland Security and granted conditional permanent residency. Aemetis plans to initiate a Phase II offering, targeting an additional $50 million to create approximately 2,000 jobs for 200 investors. The project has gained National Interest Expedite (NIE) approval for expedited processing of investor applications.

Aemetis (NASDAQ: AMTX) announced FDA approval for the production and marketing of Over The Counter sanitizer products through its subsidiary, Aemetis Health Products. This registration allows Aemetis to meet the rising demand for hand sanitizers and related products during the COVID-19 pandemic, positioning the company as a unique large-scale sanitizer alcohol producer in the Western U.S. The global hand sanitizer market was valued at approximately $2.9 billion in 2019 and has seen significant growth due to the pandemic.

Aemetis, Inc. (NASDAQ: AMTX) has completed the construction of its first two dairy digesters and a four-mile pipeline for producing Renewable Natural Gas (RNG). This project aims to supply below-zero carbon intensity RNG, replacing petroleum-based natural gas at its Keyes ethanol facility and fueling RNG trucks and buses. The company is also advancing its Central Dairy Digester Project with plans for additional dairy partnerships and pipeline installations. These initiatives are expected to enhance revenue and reduce carbon intensity while supporting the conversion of methane from dairy waste into sustainable energy.

Aemetis announced on August 18, 2020, that it has regained compliance with NASDAQ Listing Rules. The company received confirmation from NASDAQ that it has maintained a minimum market value of publicly held shares of $15 million and a closing bid price of at least $1.00 per share for 10 consecutive trading days. This compliance determination resolves prior concerns regarding its listing status. Aemetis specializes in advanced renewable fuels and biochemicals, operating facilities in California and India, and is engaged in innovative projects aimed at producing sustainable energy alternatives.

Aemetis, Inc. (NASDAQ:AMTX) reported second-quarter 2020 earnings of $0.10 per share and net income of $2.2 million, significantly improving from a net loss of $13.9 million in Q2 2019. Revenues reached $47.8 million, driven by high-grade alcohol sales for hand sanitizers, despite a decline from $50.6 million in the previous year. Gross profit rose to $14.1 million from $3.3 million YoY. Adjusted EBITDA increased to $11.2 million. Aemetis is expanding its production to include USP-grade alcohol by Q1 2021, anticipating continued market growth.